Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.
- Author:
Hyo Sup SHIM
1
;
Jin Haeng CHUNG
;
Lucia KIM
;
Sunhee CHANG
;
Wan Seop KIM
;
Geon Kook LEE
;
Soon Hee JUNG
;
Se Jin JANG
Author Information
1. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.
- Publication Type:Review
- Keywords:
Mutation;
Receptor, epidermal growth factor;
Guideline
- MeSH:
Humans;
Korea;
Lung;
Lung Neoplasms;
Patient Selection;
Protein-Tyrosine Kinases;
Quinazolines;
Receptor, Epidermal Growth Factor;
Erlotinib Hydrochloride
- From:Korean Journal of Pathology
2013;47(2):100-106
- CountryRepublic of Korea
- Language:English
-
Abstract:
Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.
